Liver King TRT: Clinical Interpretation of His Admitted PED Use

What Liver King Actually Admitted to Taking

Brian Johnson spent approximately two years building an audience of more than 10 million social media followers on the premise that his physique resulted entirely from eating raw organs, sunlight, cold exposure, and what he called the "nine ancestral tenets." He explicitly and repeatedly denied using any drugs.

That narrative collapsed in November 2022 when Derek of the YouTube channel More Plates More Dates published what he described as an email from Johnson to a fellow influencer. Johnson subsequently released a public video apology confirming the email was genuine.

The Leaked Email: Specific Compounds Named

The email itemized a compound list that included:

• Testosterone at supraphysiologic doses
• Human growth hormone (HGH), also referenced as somatropin
• Insulin (a fast-acting form, used periworkout to drive nutrient uptake)
• IGF-1 LR3 (a synthetic long-acting analogue of insulin-like growth factor 1)
• Peptides including BPC-157 and TB-500
• Thyroid hormone (likely T3/liothyronine based on context)
• Additional compounds consistent with anabolic cycles

Johnson confirmed this list in his video statement, though he framed several items as medically supervised. He did not release lab records or prescribing physician details publicly.

What "Medically Supervised" Means Clinically

The phrase "medically supervised" covers a wide range of arrangements. Legitimate testosterone replacement therapy requires documented hypogonadism (two morning serum testosterone measurements below 300 ng/dL per the Endocrine Society Clinical Practice Guideline) [1], plus an assessment of symptoms. The guideline states directly: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term, have uncontrolled heart failure, or have a hematocrit above 54%." [1]

Prescribing testosterone, insulin, and HGH simultaneously to a eugonadal man for physique purposes is not a guideline-supported practice and falls outside FDA-approved indications for each drug.

Clinical Pharmacology of Each Admitted Compound

Testosterone at Supraphysiologic Doses

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, halting endogenous production within days to weeks. At replacement doses (targeting 400 to 700 ng/dL serum trough), the Endocrine Society reports a favorable benefit-to-risk profile for men with confirmed hypogonadism [1].

At supraphysiologic doses, the risk profile shifts substantially. A 2023 meta-analysis in the Journal of the American College of Cardiology (N=5,033 across 35 trials) found that anabolic-androgenic steroid (AAS) use was associated with a 2.3-fold increase in the odds of major adverse cardiovascular events compared with non-users [2]. Left ventricular hypertrophy was detectable on echocardiography in roughly 58% of long-term AAS users in that dataset [2].

Polycythemia is another well-documented dose-dependent effect. Hematocrit above 54% substantially increases blood viscosity and thrombotic risk. The FDA label for testosterone cypionate lists thromboembolic events as a boxed-warning concern [3].

Human Growth Hormone

Recombinant human growth hormone (somatropin) is FDA-approved for adult growth hormone deficiency, which requires provocative testing to confirm. Off-label cosmetic or performance use carries meaningful risks.

A study published in Annals of Internal Medicine (N=303) found that GH supplementation in healthy older adults produced modest lean mass gains of approximately 2 kg but no improvement in strength, while increasing rates of soft-tissue edema (39%), arthralgia (41%), and carpal tunnel syndrome (24%) [4]. Prolonged supraphysiologic GH exposure is associated with acromegalic changes including jaw and brow prominence, visceromegaly (organ enlargement), and insulin resistance.

Johnson's physique showed features that physicians have publicly noted as consistent with visceromegaly, particularly the pronounced abdominal distension common in long-term GH and insulin users.

Insulin

Non-diabetic use of exogenous insulin is acutely life-threatening. Hypoglycemic episodes can cause seizure, cardiac arrhythmia, or death within minutes if glucose supplementation is not immediately available.

Insulin drives glucose and amino acids into muscle cells periworkout, an effect bodybuilders attempt to exploit for hypertrophy. No randomized trial in non-diabetic, non-hospitalized populations supports this practice, and the FDA has not approved any insulin product for body composition in euglycemic individuals [5].

IGF-1 LR3

IGF-1 LR3 is a synthetic peptide analogue not approved for human use by the FDA. It binds IGF-1 receptors with longer half-life than endogenous IGF-1 (approximately 20 to 30 hours versus 5 to 6 minutes). Animal studies suggest mitogenic effects, including potential stimulation of pre-existing cancer cell lines [6]. Human safety data are limited to case reports and small observational series. The NIH National Cancer Institute notes elevated circulating IGF-1 is associated with increased risk of colorectal, prostate, and breast cancers in epidemiological cohorts [6].

BPC-157 and TB-500

These peptides are research compounds. BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide derived from a gastric protein. TB-500 is a synthetic fragment of thymosin beta-4. Both circulate in the longevity and biohacking communities.

Rodent data on BPC-157 show accelerated tendon-to-bone healing and gastroprotective effects [7]. No Phase II or Phase III human trials have been completed as of mid-2025. TB-500 has no published human randomized controlled trials. Neither compound is FDA-approved for human use.

Why the Liver King Case Matters Clinically

The Problem of Informed Consent Under False Pretenses

Johnson built a supplement business (Ancestral Supplements) during the same period he was, by his own admission, using an $11,000-per-month drug stack. Men who purchased supplements believing they could replicate his physique through diet alone were operating under a materially false premise. This is not a trivial concern. A 2021 survey by the CDC National Center for Health Statistics found that 57.6% of U.S. Adults used at least one dietary supplement, with body composition goals cited by 30% of male users [8]. Marketing that falsely attributes a drug-aided physique to supplementation directly misleads that population.

Distinguishing PED Abuse from Medical TRT

Men who present to a clinic asking about testosterone after following influencers like Liver King often conflate two very different things: medically supervised testosterone replacement in hypogonadal men and supraphysiologic AAS cycling for physique.

The clinical distinction matters. The Endocrine Society's 2018 guideline defines hypogonadism as a serum total testosterone consistently below 300 ng/dL alongside symptoms including reduced libido, fatigue, decreased muscle mass, and mood disturbance [1]. Men meeting those criteria benefit from TRT with a well-characterized safety profile when doses are titrated to mid-normal range (400 to 700 ng/dL).

Supraphysiologic dosing, stacking multiple anabolics, and adding insulin or GH to a TRT regimen is a categorically different intervention with a categorically different risk profile. A clinician who conflates the two, or who prescribes without documented indication, risks patient harm and regulatory sanction.

HealthRX Clinical Framework: TRT vs. PED Stack

| Feature | Medical TRT | Supraphysiologic PED Stack | |---|---|---| | Indication | Documented hypogonadism (<300 ng/dL x2) | None (off-label, non-approved) | | Target serum testosterone | 400 to 700 ng/dL | Often 1,500 to 3,000+ ng/dL | | Monitoring required | Hematocrit, PSA, lipids q3-6 months | No standardized protocol | | FDA approval | Yes (cypionate, enanthate, gel, patch) | No | | Fertility impact | Reversible with HCRT/clomiphene in most cases | Variable; may require prolonged recovery | | CV risk at therapeutic dose | Slight increase; generally manageable | Substantially elevated | | Concurrent GH/insulin use | Not indicated; not standard of care | Common in PED stacks; not approved |

The Lawsuit and Its Clinical Implications

A class-action lawsuit was filed against Ancestral Supplements in early 2023, alleging deceptive marketing practices tied to Johnson's undisclosed PED use. Legal proceedings are ongoing as of this article's publication. The suit is clinically notable because it establishes a potential liability framework for supplement companies whose spokespeople use undisclosed drugs while implying their physiques are supplement-derived.

Cardiovascular and Metabolic Consequences of the Admitted Stack

Cardiac Risk

The combination of supraphysiologic testosterone, HGH, and insulin in Johnson's admitted regimen represents a pharmacologically aggressive stack. Each compound independently affects cardiovascular structure and function.

Testosterone at high doses increases red blood cell mass (hematocrit), raises LDL cholesterol, and promotes left ventricular hypertrophy. HGH at supraphysiologic doses causes sodium and water retention, increasing cardiac preload. Insulin, in repeated doses, drives adipose deposition in atypical patterns and may promote smooth muscle proliferation in vessel walls over years of use.

A 2020 study in Circulation (N=140) found that competitive male bodybuilders with prior AAS use had a mean left ventricular mass index 30% higher than non-using controls, and coronary artery calcification scores approximately four times higher [9]. The authors concluded: "Long-term anabolic-androgenic steroid use is associated with a pattern of cardiovascular disease that includes cardiomyopathy, dyslipidemia, and accelerated atherosclerosis." [9]

Endocrine Disruption

Prolonged exogenous testosterone suppresses LH and FSH, causing testicular atrophy and azoospermia. Recovery after cessation is not guaranteed. A 2020 review in Fertility and Sterility found that 25% of men who used AAS for more than two years had persistent oligospermia 12 months after stopping, and 5% had permanent azoospermia [10].

Adding exogenous HGH suppresses endogenous GH pulsatility. If used before epiphyseal closure (age <18), GH analogues can accelerate or disrupt bone maturation.

Hepatotoxicity

Oral 17-alpha-alkylated androgens (common in PED stacks, though not explicitly confirmed in Johnson's list) carry well-documented hepatotoxic risk. Injectable testosterone esters are generally hepatically safer, but cases of peliosis hepatis and cholestatic jaundice have been reported with injectable supraphysiologic regimens [11].

What Men Should Ask Their Prescriber After Reading This

The Liver King case offers a useful set of clinical prompts for men evaluating their own hormonal health.

Questions Worth Bringing to a TRT Consultation

1. "Can you show me my two baseline morning testosterone levels, drawn before 10 a.m., and confirm both are below 300 ng/dL?" The Endocrine Society requires two separate measurements for diagnosis [1].
2. "What target serum testosterone level are we aiming for, and will you monitor hematocrit and PSA every three to six months?" Monitoring frequency is specified in the American Urological Association testosterone guideline and Endocrine Society documents [1].
3. "Is there any indication for adding HGH or peptides to my protocol?" In men with normal IGF-1 levels and no documented GH deficiency, the answer should be no.
4. "Does your practice have a documented protocol for fertility preservation if I want children in the future?"

A prescriber who cannot answer these questions specifically, or who offers a multi-compound stack without documented hormone deficiencies, is operating outside guideline-supported care.

The "Nine Ancestral Tenets" and the Reality of Natural Physique Development

Johnson promoted sun, sleep, eating, movement, shield (stress management), cold exposure, bond (social connection), and fight training as the complete blueprint for his physique. Each tenet has at least some peer-reviewed support for general health benefit. None, individually or combined, produces a physique of the mass and leanness he displayed without substantial androgenic and anabolic assistance in the available sports science literature.

A 2020 review in the Journal of Strength and Conditioning Research found that elite natural bodybuilders competing in drug-tested organizations typically achieve a fat-free mass index (FFMI) of 22 to 24 [12]. Johnson's publicly available photos are consistent with an FFMI above 28, a threshold that requires either extraordinary genetic outlier status or exogenous anabolic support based on the distribution of FFMI values in research populations [12].

This is not a moral judgment. It is a clinical observation. Men who set physique expectations based on bodies built with undisclosed PEDs face not just disappointment but potential harm if they pursue those goals through escalating supplement doses or, worse, unsupervised drug use.

Semaglutide, GLP-1, and the Broader Telehealth Hormone Field

Johnson's case sits in a broader context of growing consumer demand for performance and aesthetics-focused hormone prescribing. Legitimate GLP-1 agonists (semaglutide, tirzepatide) prescribed by telehealth physicians for documented obesity (BMI <30 with comorbidities or BMI <35 without) represent evidence-based care at the opposite end of the spectrum from PED stacks. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [13]. These are guideline-supported interventions with strong trial data.

The contrast is stark. Patients and clinicians deserve clarity about which compounds have that evidence base and which do not.